Why MAIA Biotechnology’s ateganosine program is entering a decisive lung cancer development phase
Find out how MAIA Biotechnology’s ateganosine trials could shape the next phase of lung cancer drug development today.
MAIA Biotechnology advances ateganosine cancer program with Phase 3 THIO-104 trial and 2026 catalyst timeline
Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.